Kornimate/medical-research-clean huggingface dataset:
imaging of soft tissues

Conditions: Soft Tissue Injury

Summary: the purpose of this study is to evaluate the potential importance of tissue elasticity in the assessment of soft tissues including muscles, tendons and ligaments and other soft tissue structures. the evaluation of tissue elasticity (easily stretched or moveable) may assist in assessment of various soft tissue structures, such as fatty atrophy of muscles, tendon/ligamentous injury and healing and other soft tissue structures.

this is a prospective study that will recruit males and females 18 years of age and older who present to the department for a clinically indicated ultrasound of a superficial soft tissue abnormality with prior or following mri / ct assessment ordered for clinical purposes. the elasticity properties of tissues depend on their molecular building blocks and on the organization of these blocks. injuries, disease etc are known to be associated with changes in tissue elasticity. little research has been done on the potential of sonoelastographic (elasticity ultrasound imaging) assessment of normal, injured or healing muscles, tendons or ligaments. elasticity changes in muscle, ligaments and tendons following injury may have implication on the choice of treatment and help in determine how the length of time needed to heal from an injury. stiffness/elasticity of the tissue can be assessed by mechanical excitation with measurement of resultant tissue motion. reconstruction of the elastic deformability (strain imaging) in real time ultrasound is known as sonoelastography. elasticity ultrasound imaging will be performed on the area being evaluated clinically.

Eligibility criteria:
inclusion criteria: * subjects who present for a clinically ordered ultrasound for evaluation of a soft tissue abnormality. exclusion criteria: * women who are pregnant
bariatric surgery and the kidney

Conditions: Proteinuria

Summary: the purpose of the project is to study the relationship between post-bariatric surgery changes in weight and renal parameters.


Eligibility criteria:
inclusion criteria: * bariatric patients exclusion criteria: * age \<18 * dialysis dependency

Keywords: glomerular filtration rate
effects of intravenous lidocaine on endometriosis pain

Conditions: Endometriosis

Summary: we are doing this research study to find out if intravenous (in your vein, "iv") lidocaine can lessen pain from endometriosis. the u.s. food and drug administration (fda) has approved intravenous lidocaine to treat irregular heart beats, but the fda has not approved intravenous lidocaine to treat pain from endometriosis. intravenous lidocaine has been used for more than 25 years to treat different acute and chronic pain conditions but has not yet been studied for endometriosis pain. this is a cross-over trial over two months where one month you will receive the active medication (lidocaine) and one month you will receive the active placebo (diphenhydramine, commonly known as benadryl). we will compare the effect on pain from endometriosis of lidocaine to active placebo.


Eligibility criteria:
inclusion criteria: * reproductive age women ages 18 - 50 * endometriosis diagnosed laparoscopically or by primary care physician or gynecologist using clinical criteria * pain for \> 6 months * pain most intense around time of menstrual cycle. pain at least 5 on a 0-10 scale. * receiving regular monthly menses (cannot be receiving depo-provera injections) exclusion criteria: * pregnant or breastfeeding * on lupron therapy * history of myocardial infarction or cardiac arrhythmias including wolff-parkinson-white, severe sinoatrial, atrioventricular or intraventricular heart block in the absence of a pacemaker * history of seizure disorder * significant anxiety, psychosis or other cognitive disorder limiting completion of study procedures * history of alcohol or substance abuse * chronic pain symptoms other than chronic pelvic pain (excluding migraine pain) * known hypersensitivity to amide type anesthetics * known hypersensitivity to diphenhydramine (benadryl) * history of treatment with lidocaine or mexiletene * having or showing signs and symptoms of liver disease

Keywords: endometriosis chronic pain intravenous lidocaine
the effect of stress ball application before coronary angiography on stress, anxiety and vital signs

Conditions: Coronary Artery Disease

Summary: it aimed to examine stress, anxiety and resorting to life paths to enable researchers to contain this stress.

stress and anxiety lives of patients before coronary angiography. the stress and anxiety they experience also affect their vital signs. the researchers aimed to examine the ways the stress ball affected their patients' stress, anxiety, and vital signs.

Eligibility criteria:
inclusion criteria: * 18 years and over * for those who will undergo coronary angiography for the first time * able to read and write * not diagnosed with anxiety disorder and not using medication for it * no physical disability to use the stress ball * cognitive health levels consist of individuals who are suitable for answering data collection forms. exclusion criteria: * unconscious and not fully oriented * sight and hearing problems * alzheimer's disease and other types of dementia * having a severe psychiatric problem that cannot answer the questions * those who came with mi (myocardial infarction) and performed cag * individuals who are closed to communicating are not included in this study.

Keywords: coronary angiography stress anxiety vital signs
assessment of thyroid doppler ultrasound in followup of pediatric graves' disease

Conditions: Graves' Disease

Summary: all cases of the study will be diagnosed as graves' by history, examination, laboratory (ft3, ft4, tsh \& trabs), x-ray on left wrist for bone age, neck grey scale ultrasonography for thyroid gland size, shape, echotexture, vascularity and nodule characters if present with tirad score calculation. then color flow doppler ultrasound will be done to asses thyroid volume, number of vessels per square cm and inferior thyroid artery peak systolic velocity, end diastolic velocity and resistive index. patients then will receive carbimazole antithyroid drug at dose 0.25-0.5 mg/kg/day po \& the dose will be titrated according to thyroid function test after 4-6 weeks. beta-adrenergic blockade will be added to all symptomatic cases. regular follow up will be done every month of first 3 months of diagnosis and then every 3 months for 2 years by clinical and thyroid function test to asses response, compliance, complications, drug side effects, remission and relapses. doppler ultrasound will be done at 0, 12 and 24 months.


Eligibility criteria:
inclusion criteria: * all newly diagnosed children with clinical and laboratory hyperthyroidism (high t4 \& low tsh) with positive trabs. exclusion criteria: * patients receiving radioiodine patients underwent thyroid surgery history of neck radiation or neck surgery
study of mk-8808 for participants with follicular lymphoma (mk-8808-001)

Conditions: Follicular Lymphoma

Summary: this study will evaluate the safety, pharmacokinetics, and anti-tumor activity of mk-8808 in combination with cyclophosphamide, vincristine, and prednisolone (cvp), and as a single agent, for participants with b-lymphocyte antigen cluster of differentiation 20 (cd20)-positive follicular lymphoma who have had no prior chemotherapy. the primary study hypothesis is that mk-8808 will be safe and well tolerated in combination with cvp and as a single agent.

the study was terminated early by the sponsor due to business reasons. all participants were discontinued from mk-8808 + cvp, but could continue to receive maintenance therapy with mabthera™ (rituximab) per standard of care.

Eligibility criteria:
inclusion criteria: * histological diagnosis of cd20-positive follicular lymphoma, grade 1, 2, or 3a (world health organization \[who\] 2008 classification) based on an excisional or incisional lymph node biopsy or a bone marrow biopsy. * ann arbor stage iii or iv disease. * eastern cooperative oncology group (ecog) performance status of ≤2. * life expectancy \>3 months with no expected need of immediate intervention to treat life-threatening complications. * adequate organ function. * participants must agree to use an adequate method of contraception starting with the first dose of study drug through 12 months (for females) or 90 days (for males) after the last dose of study drug. exclusion criteria: * histological grade 3b or with \>50% diffuse architectural pattern. * circulating malignant cells \>25,000/mm\^3 * presence or history of central nervous system (cns) disease (either cns lymphoma or lymphomatous meningitis). * prior treatment with chemotherapy, rituximab, any other anti-cd20 compound, or any other type of anti-cancer compounds. * radiotherapy within 2 months prior to cycle 1 day 1. * current participation or has participated in a study with an investigational compound within 30 days prior to cycle 1 day 1. * concomitant disease that requires continuous therapy with prednisone at doses \>20 mg per day. * any medical contraindication for prednisolone as being dosed in the cvp regimen. * poorly controlled diabetes mellitus, as defined by institutional or local standards. * grade \>2 peripheral neuropathy. * has one of the following: 1. is human immunodeficiency virus (hiv)-positive 2. is hepatitis b surface antigen positive (hbsag+) or is positive for antibodies to hepatitis b core antigen (anti-hbcag+) 3. has antibodies to hepatitis c virus * has one or more of the following: 1. active tuberculosis based on institutional diagnostic criteria and local practice guidelines. 2. evidence of a tuberculosis infection based on a chest x-ray (cxr) or computed tomography (ct) scan performed within 3 months of dosing. 3. history of a tuberculosis infection. * major surgical procedure within 4 weeks prior to cycle 1 day 1. * regular use (including "recreational" use) of any illicit drugs or recent history (within the last year) of drug or alcohol abuse or dependence. * pregnant or breastfeeding.
next science wound gel efficacy in chronic wound versus standard of care

Conditions: Wound Chronic Draining

Summary: this is a 3 to 4 months, multi-site, prospective randomized clinical study of patients diagnosed with a chronic wound. the primary objective is to assess changes in healing rate, by measuring differences in wound area when treating chronic wounds with the next science wound gel compared to the triple antibiotic ointment neosporin (standard of care, soc). at the end of the study period, patients may continue receiving their assigned study treatment provided they have signed the "continuation of treatment informed consent" and the rational for continuation is documented by the investigator.


Eligibility criteria:
inclusion criteria: * male or female 18 years or older * presence of full-thickness wound for more than one month (i.e. chronic) * ulcer must be greater than 1 centimeter in area to enable biofilm sampling * not a candidate for vascular reconstructive surgery to restore blood flow to the wound * willing to comply with all study procedures and be available for the duration of the study * provide signed and dated informed consent exclusion criteria: * subjects unable to provide signed and dated informed consent * male or female less than 18 years old * presence of a full-thickness wound for less than one month * a candidate for vascular reconstructive surgery to restore blood flow to the wound * subjects with bleeding dyscrasia or with medical conditions that would make a bleeding complication likely * subjects who's wound is less than 1 cm precluding adequate wound biofilm sampling * subject with known allergic reaction to the study products
acoustic stimulation for seizure suppression

Conditions: Epilepsy

Summary: the objective of this study is to test the feasibility and physiological effect of low-frequency (1 hz) acoustic stimulation delivered during nocturnal nrem sleep in epilepsy patients. the long-term goal is to develop this protocol for daily, long-term use in a home setting, for nocturnal seizure and ied suppression

1. to test the feasibility of wearing an earphone system delivering acoustic stimulation during a night of sleep in adult epilepsy patients monitored in an inpatient unit. 2. to determine the acute physiological effects of low-frequency acoustic stimulation on interictal epileptiform discharge (ied) frequency during nrem sleep in adult patients with epilepsy in an ambulatory setting. 3. to determine the feasibility of applying low-frequency acoustic stimulation in a long-term home setting in adult epilepsy patients with frequent nocturnal seizures.

Eligibility criteria:
inclusion criteria: * 18-60 years old * able to provide informed consent * moca ≥26 * fluent in english * frequent nocturnal ieds (≥ 10% of the sleep record) * monitored on the adult epilepsy monitoring unit (emu, for aim 1 only) additional inclusion criteria for aim 3 * frequent nocturnal seizures (≥1 per week) exclusion criteria: * hearing impairment * diagnosis of a sleep disorder (sleep apnea, periodic limb movements of sleep, or other medical conditions with frequent arousals) * psychoactive medication use (other than aeds, for example ssris, antipsychotics, bdz, or stimulants) * seizures ≤ 24 hours prior to study. * alcohol or recreational drug use in the 24 hours prior to the study * bmi ≥ 30 * moca \<26 * history of recent travel across time zones within the 1 month prior to study activities * shift work for 1 month prior to study activities additional exclusion criteria for aim 3 * no medication changes at least 1 month before study, and during 3 months of study activities
efficacy and safety of ceftazidime-avibactam (caz-avi) in chinese participants with hap (including vap)

Conditions: Hospital-Acquired Pneumonia

Summary: this is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of caz-avi in participants with hap (including vap), who have initiated treatment with caz-avi in an inpatient hospital setting. the duration of antibiotic treatment with the caz-avi is 7-14 days. participants must receive intravenously (iv) caz-avi in the hospital for at least 7 full days. there are no formal hypothesis tests planned for this study. the number and percent of participants having clinical cure, failure, and indeterminate at toc visit in the cmitt analysis population will be summarized.


Eligibility criteria:
inclusion criteria: * male or female participants ≥18 and ≤90 years of age. * onset of symptoms ≥48 hours after admission or \<7 days after discharge from an inpatient acute or chronic care facility. * new or worsening infiltrate on chest x-ray obtained within 48 hours prior to screening. * participants have systemic signs and respiratory signs or symptoms of hap/vap exclusion criteria: * other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * participant is expected to require a treatment course for hap longer than 14 days. * the total duration of antibiotic exposure for antibiotics whose administration begins in the 48 hours is longer than 24 hours. * previous administration with an investigational drug within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). * acute physiology and chronic health evaluation (apache) ii score \>30 or \<10 using the most recent available data.
a study of dose escalation of ibi321 in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and primary efficacy of ibi321 in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable.


Eligibility criteria:
inclusion criteria: 1. subjects able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures. 2. patients with advanced solid tumors who had failed standard treatment. 3. male or female subjects ≥18 years and ≤75 years. 4. at least one measurable lesion per recist version 1.1 5. eastern cooperative oncology group (ecog) performance status ≤1 6. life expectancy of ≥ 12 weeks. 7. adequate hematologic and end organ function exclusion criteria: 1. any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, targeted therapy, or immunotherapy. 2. failure to recover from adverse events from the most recent anti-tumor 3. acute or chronic hepatitis b, hepatitis c or human immunodeficiency virus (hiv) infection. 4. subjects with cns metastasis unless they are asymptomatic or adequately treated with radiotherapy and/or surgery and subjects are neurologically stable with minimal residual symptoms/signs. 5. any other serious underlying medical (e.g., uncontrolled hypertension, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, other serious cardiac conditions not listed in exclusion criteria), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. 6. pregnancy, lactation, breastfeeding.
vitamin d supplementation for the prevention of cardiovascular risk

Conditions: Obesity; Overweight; Insulin Resistance

Summary: hypovitaminosis d is highly prevalent in the general population, particularly in obese individuals. besides being associated with obesity, vitamin d deficiency seems to be involved in the pathogenesis of insulin resistance and low-grade chronic inflammation. in addition, it has been reported that individuals with low vitamin d levels are at increased risk for cardiovascular diseases. a healthy diet and weight loss are cornerstones in the prevention of cardiovascular diseases. vitamin d supplementation could increase the beneficial effects of these lifestyle interventions. the purpose of this study is to assess whether vitamin d supplementation in conjunction with a hypocaloric diet improves the cardiometabolic profile of overweight/obese subjects to a greater extent than diet alone.


Eligibility criteria:
inclusion criteria: * bmi≥25 kg/m2 exclusion criteria: * diabetes mellitus * chronic kidney disease * liver disease * cholestasis * cancer * chronic bowel disease * primary or secondary hyperparathyroidism * treatment with drugs that may affect insulin sensitivity, weight or calcium/vitamin d metabolism * laxative abuse * changes \>10% of usual body weight in the previous 6 months * alcohol or illicit drug abuse * pregnancy

Keywords: obesity insulin resistance vitamin d cardiovascular risk factors
reduction of metabolic acidosis in patients with chronic kidney disease in stage 4 and 5

Conditions: Kidney Diseases; Metabolic Acidosis; Renal Insufficiency; CKD; Pre-dialysis

Summary: the goal of this clinical trial is to learn about and test the effect of an acid/base diet, in chronic kidney patients with ckd stage 4 and 5 in an interventional study with a historical control. the hypothesize is, that an acid/base diet will reduce the degree of acidosis and the need for oral bicarbonate supplements.

observational studies indicate that diets with a low "potential renal acid load (pral)" is associated with a lower serum-bicarbonate value. the aim is to investigate this association with an interventional studydesign. participants will be asked to follow a restricted diet with a low "pral" during a 6 week trial divided in three periodes: two week free living control, two week intervention and a two week free living follow-up. the pral calculation tool will be used to create a diet low in acid, based on this the patients will receive individual diet plans. the diet will comply with national treshold guidelines for potassium and protein, this is due to the high risk of hyperkalemia in patients with chronic kidney disease. the patients will be asked to document their food and drink intake by taking pictures of their plates and cups before and after a meal, over a 24 hour period.

Eligibility criteria:
inclusion criteria: * chronic acidosis (plasma-bicarbonat under 22 mmol/l at multiple measures within the last 12 months). * diagnosed with non-dialysis needed chronic kidney disease in stage 4 and 5 (egfr below 30 ml/min/1,73 m2) * of legal age and over 18 of years * understand danish and understand the written material * able to cooperate about the diet * able to take pictures with their phone or willing to learn exclusion criteria: * vegan and vegetarian with very low intake of animal protein (below 25 g/day) * pregnant or breast feeding * patients with short bowel syndrome, brickre's bladder, pancreatitis or any other known malabsorption problem * potassium above 5 mmol/l * ongoing infection

Keywords: potential renal acid load pral study design diet humans elderly bicarbonate/blood muscle strength hand strength chair stand test calorimetry, indirect bone mineralization carbon dioxide/blood phosphor/urine potassium/urine urea/blood urea/urine
evaluation of patients with suspected endofibrosis

Conditions: Peripheral Artery Disease

Summary: define responses to exercise on both arterial bruits and oxymetry in patients referred for suspected endofibrosis.

recording of oxymetry during exercise and recovery. recording of vascular bruits at rest ajnd post exercise.

Eligibility criteria:
inclusion criteria: referred for exercise test - exclusion criteria: none -